NeuroSense Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 16
- Market Cap
- -
- Website
- http://www.neurosense-tx.com
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.
- First Posted Date
- 2023-12-29
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06185543
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject
Phase 1
Completed
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT05436678
- Locations
- 🇺🇸
Novum, Las Vegas, Nevada, United States
A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
Phase 2
Active, not recruiting
- Conditions
- Amyotrophic Lateral SclerosisALS
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT05357950
- Locations
- 🇮🇹
IRCCS Istituti clinici Maugeri, Milano, Italy
🇮🇹A.O.U. Citta della Salute e della Scienza di Torino, Torino, Italy
🇨🇦Lawson Health Research Institute, London, Ontario, Canada
A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05232461
- Locations
- 🇺🇸
Novum, Fargo, North Dakota, United States
Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS
Phase 2
Completed
- Conditions
- Amyotrophic Lateral SclerosisALS
- Interventions
- Drug: Fixed dose combination Ciprofloxacin/Celecoxib
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04165850
- Locations
- 🇮🇱
Sourasky Medical Center, Tel Aviv, Israel
Ciprofloxacin/Celecoxib Combination in Patients With ALS
Phase 1
Completed
- Conditions
- ALS (Amyotrophic Lateral Sclerosis)
- Interventions
- Drug: Fixed dose combination Ciprofloxacin/Celecoxib
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT04090684
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath